



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Spironolactone-d₇

Cat. No.:	HY-B0561S
Molecular Formula:	C ₂₄ H ₂₅ D ₇ O ₄ S
Molecular Weight:	423.62
Target:	Androgen Receptor; Autophagy; Mineralocorticoid Receptor; Isotope-Labeled Compounds; Calcium Channel
Pathway:	Vitamin D Related/Nuclear Receptor; Autophagy; Metabolic Enzyme/Protease; Others; Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Spironolactone-d ₇ is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC ₅₀ of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC ₅₀ of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. *J Clin Aesthet Dermatol*. 2012;5(3):37-50.
- [3]. Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. *J Biol Chem*. 2010;285(39):29932-29940.
- [4]. Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. *Int Urol Nephrol*. 2019;51(4):755-764.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA